GLYC
$10.10
Glycomimetics
($.19)
(1.85%)
GLYC
Earnings Whisper ®
N/A
4th Quarter December 2018
Consensus:  ($0.30)
Revenue:  N/A
Friday
Feb 1
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when GLYC reports earnings?
Beat
Meet
Miss

Where is GLYC's stock price going from here?
Up
Flat
Down
Stock chart of GLYC
Analysts
Summary of analysts' recommendations for GLYC
Score
Grade
Pivots
Resistance
$11.50
$11.17
$10.73

$10.40

Support
$9.96
$9.63
$9.19
Tweet
Growth
Description
GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
Peers
Vertex PharmaceuticalsBioMarin PharmaceuticalRegeneron PharmaceuticalsCelgeneEndo International plcUltragenyx PharmaceuticalMylanInterCeptJohnson & JohnsonPerrigo